Navigation Links
MabVax Therapeutics Receives $1.8 Million in a Phase 2 Small Business Innovation Research Program Award From the National Cancer Institute
Date:4/11/2011

herapy, the majority of these patients with recurrent sarcoma die as a result of further recurrences.  

The vaccine is designed to instruct the patient's immune system to make antibodies against the three ganglioside antigens present on the surface of sarcoma cells. The antibodies are expected to seek out and eliminate residual circulating cancer cells and micrometastases. The vaccine was developed at Memorial Sloan-Kettering Cancer Center (MSKCC) where preclinical and early clinical development work was completed in 2009.  MabVax exclusively licensed the sarcoma vaccine, along with additional vaccines targeting other neuroectodermal and epithelial cancers, from MSKCC in 2008.  

Additional information may be obtained by following the link to the clinicaltrials.gov website.

About MabVax Therapeutics, Inc.

MabVax Therapeutics, Inc. is a clinical stage biotechnology company focused on the development of vaccine and antibody based therapies to address the unmet medical need of preventing recurrent cancer. The company was formed to exploit key aspects of the work of Dr. Philip Livingston and colleagues at MSKCC who have developed cancer vaccines against gangliosides and other carbohydrate antigens that are the most extensively expressed antigenic targets on the cell surface of certain cancers. The company believes that passively administered or vaccine induced antibodies against selected tumor cell surface antigens are ideally suited for eradication of free tumor cells and micrometastases that remain after initial treatment and cause cancer recurrence.  The company plans to commercially develop vaccines against several different types of cancer over the coming years.  Concurrently, MabVax is creating a pipeline of monoclonal antibody products based on the protective immune responses generated by patients who have been immunized against targeted cancers. The company i
'/>"/>

SOURCE MabVax Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. MabVax Therapeutics Receives Small Business Innovation Research Program Award from the National Cancer Institute
2. Halozyme Therapeutics Reports 2008 Second Quarter Financial Results
3. Repair Stem Cell Institute Announces Industrys First Standards of Excellence for Global Stem Cell Treatment Centers to Protect Patients from Less-than-Competent Therapeutics
4. Amsterdam Molecular Therapeutics Reports Half Year Results 2008
5. BN ImmunoTherapeutics Announces Partnership With National Cancer Institute
6. Arno Therapeutics Announces Appointment of Brian Lenz, CPA as Chief Financial Officer
7. CV Therapeutics Announces Ranexa(R) Named Finalist for Prix Galien USA 2008 Award
8. CV Therapeutics Receives European Approval for the Brand Name Ranexa(R)
9. Nile Therapeutics, Inc. Reports 2008 Second Quarter Financial Results
10. Cell Therapeutics, Inc.s Second Quarter 2008 Financial Results
11. Logical Therapeutics Inc. Announces Results of Phase 1b Clinical Study of its Naproxen Prodrug
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... January 15, 2014 This webinar ... on nonclinical and clinical safety assessment in biosimilars. ... guide a path for biosimilar drug development, however ... of biosimilarity with regards to quality, safety and ... of biosimilar drug development and registration, development strategies ...
(Date:1/15/2014)... NC (PRWEB) January 15, 2014 ... an enhancement to its Online Web Portal for Life ... now have the ability to specify the subject matter ... nearly 50 life science sub-domains. This will help reduce ... and scientific fields, and decrease the likelihood of error. ...
(Date:1/14/2014)... Doylestown, PA (PRWEB) January 14, 2014 ... – 11 p.m. , Location: Warrington Country Club, 1360 ... Hepatitis B Foundation, the only national nonprofit organization solely ... improving the quality of life for those affected worldwide, ... 11 at Warrington Country Club in Warrington, Pa. ...
(Date:1/14/2014)... York, NY (PRWEB) January 14, 2014 ... initiated coverage of Alliqua, Inc. (OTCQB: ALQA). Alliqua ... and marketing proprietary products to serve the wound ... , In late 2012, Alliqua was restructured ... launched the company’s new strategy to become a ...
Breaking Biology Technology:Xtalks Life Sciences Webinar Examines Safety Assessment of Biosimilars 2DTS Improves Efficiency for Life Science Document Translations 2Hepatitis B Foundation to Host Annual Crystal Ball Gala 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 3
... 2008 R&D 100 Awards Now Online, ROCKAWAY, N.J., ... the 8th Annual Innovator of the Year and 43rd ... exemplify the,ideals of R&D in academia, industry, and nationally ... with ten finalists,-- five scientists and five innovators -- ...
... TOLEDO is pleased to announce that Dr. Francis Stoessel, ... Institute (SWISSI), will be the Keynote Speaker in the ... , ... Columbia, MD ...
... ALBANY, Ore., Sept. 30 Synthetech, Inc. (OTC,Bulletin ... Frederic,Farkas as Director of Manufacturing effective on October ... consulting services to Synthetech. Dr. Farkas,has over 13 ... API,manufacturing from previous positions in manufacturing and supply ...
Cached Biology Technology:2008 R&D Innovator of the Year & Scientist of the Year Finalists Announced 2Synthetech Announces New Director of Manufacturing 2
(Date:4/15/2014)... in nanoparticle form could help reduce side effects by ... years, scientists have developed nanoparticles that deliver one or ... to design particles that can carry any more than ... have devised a new way to build such nanoparticles, ... different drugs. In a paper published in the ...
(Date:4/15/2014)... University of Adelaide research into parasites of cuttlefish, ... parasites, astonishing life cycles, and shown how they ... , Researcher Dr Sarah Catalano has described 10 ... in the kidneys of cephalopods (cuttlefish, squid and ... species to be described from Australian waters. ...
(Date:4/14/2014)... hard pill to swallow, but if you,re over 24 ... terms of your cognitive motor performance, according to a ... Thompson, a psychology doctoral student, associate professor Mark Blair, ... actuarial science doctoral student, deliver the news in a ... In one of the first social science experiments to ...
Breaking Biology News(10 mins):Targeting cancer with a triple threat 2Targeting cancer with a triple threat 3Bizarre parasite may provide cuttlefish clues 2Study says we're over the hill at 24 2
... first detailed molecular images of a piece of the spike-shaped ... and initiate the first stages of infection. The structure, which ... scientists learn new details about how the virus infects cells. ... points that can be exploited by novel antiviral drugs or ...
... the Albert Einstein College of Medicine have discovered a ... may soon be able to resist the effects of ... disease-causing microbes, including Shigella and E. coli, are rapidly ... was led by Dr. John S. Blanchard, the Dan ...
... genetics of barley could lead to improved varieties of ... whisky and beer. Scientists funded in part by the ... a new programme to uncover key genes that control ... research, being carried out at the Scottish Crop Research ...
Cached Biology News:Learning how SARS spikes its quarry 2Learning how SARS spikes its quarry 3Einstein researchers identify new way that bacteria develop resistance to antibiotics 2Whisky fans can drink to crop research 2
... Combining linear motor and ballscrew ... pre-engineered Cartesian solutions that include ... management, and motors., , ... Pass through high-flex cabling for ...
UGT1A6 (D-20)...
... T Squareds patented high efficiency dynamic valve ... With the most compact, lightweight package in ... use in portable air and gas applications., ... high efficiency. , Includes DC Motor. ...
... designed for moving loads quickly and accurately. ... output while limiting overall size. The P5S-P ... ball bearings guided on two rails., ... provide energy absorption and controlled deceleration , ...
Biology Products: